Medipostco

Medipost operates on two core pillars: cord blood banking and stem cell therapeutics. Its cord blood bank brand, Celltree, holds the No. 1 domestic market share, with cumulative cryopreserved units surpassing 333,239 as of March 2026.

Its flagship product Cartistem, an allogeneic umbilical cord blood-derived stem cell therapy for degenerative knee osteoarthritis, has grown for more than a decade since its 2012 domestic approval, with cumulative treated patients exceeding 33,000.

Domestic Cartistem sales grew from 17.2 billion won in 2021 to 21.6 billion won in 2023 before slipping slightly to 20.2 billion won in 2024, while cord blood banking revenue rose steadily from 25.8 billion won to 39.2 billion won over the same period.

Elsewhere, Pneumostem for premature-infant bronchopulmonary dysplasia and the injectable knee osteoarthritis candidate SMUP-IA-01 both completed domestic Phase 2 trials in 2024.

In contrast, the Alzheimer's candidate Neurostem failed to achieve statistical significance on its primary efficacy endpoint in a Phase 1/2a trial. Overseas, Medipost operates through its Canada-based cell and gene therapy CDMO subsidiary OmniaBio, serving North American development clients.

In December 2025 the company signed an exclusive distribution license for Cartistem in Japan with Teikoku Seiyaku, establishing a channel that could move directly to commercialization after approval.

Rising osteoarthritis prevalence tied to aging populations is a structural backdrop drawing multiple domestic and global regenerative medicine companies into similar pipelines.

Consolidated revenue reached 73.66 billion won in 2025, up 4.2% from 70.66 billion won in 2024 and a fresh record high, but the operating loss expanded nearly 40% to 6.798 billion won from 4.854 billion won a year earlier.

Net loss attributable to owners also widened from 6.253 billion won in 2024 to 8.540 billion won in 2025, deepening losses at both the operating and net income levels.

The operating margin deteriorated every year, from -27.1% in 2022 to -36.6% in 2023, -68.7% in 2024, and -92.3% in 2025, showing losses growing alongside revenue rather than narrowing.

On a quarterly basis, the operating loss eased to 14.06 billion won in Q3 2025 before widening again to 21.26 billion won in Q4, 16.85 billion won in Q1 2026, and 24.34 billion won in Q2 2026, fluctuating with the timing of clinical trial spending.

Notably, Q2 2026 posted the largest operating loss of the four recent quarters at 24.34 billion won, yet net income attributable to owners turned positive at 32.32 billion won—a swing attributed to non-operating factors rather than an improvement in core profitability.

Indeed, first-half 2026 consolidated revenue rose 3.2% year over year to 38.2 billion won while the operating loss widened to 41.2 billion won, which the company attributed to increased R&D and clinical costs for Cartistem's U.S. and Japan trials.

On a standalone basis, however, the domestic business remained profitable in H1 2026 with revenue of 41.3 billion won and operating profit of 700 million won, indicating the domestic core business partly cushions overseas clinical investment.

Operating cash flow deteriorated sharply from an outflow of 6.19 billion won in 2022 to 57.15 billion won in 2025, while the debt ratio climbed back from 43.3% in 2023 to 72.7% in 2025, reflecting growing dependence on external funding.

The knee osteoarthritis treatment market is a growth area tied to aging populations, providing the structural backdrop for domestic stem cell and regenerative medicine companies seeking overseas expansion.

Cartistem, an allogeneic stem cell therapy approved domestically in 2012, has grown for over a decade, and its accumulated long-term prescription data is being leveraged in overseas regulatory strategy.

In Japan, following completion of its Phase 3 trial, the exclusive distribution agreement with Teikoku Seiyaku secured a channel that can move to commercialization immediately after approval, with the company targeting approval within 2027.

The U.S. is regarded as the world's largest pharmaceutical market, and unlike the customary requirement of two or more independent Phase 3 trials, Medipost secured FDA acceptance of a single pivotal trial design based on long-term data from Korea and Japan plus real-world evidence.

However, multiple domestic and global cell and gene therapy developers hold similar degenerative arthritis and regenerative medicine pipelines, making proof of clinical superiority and the pace of global partnering key variables for relative positioning.

The company has also restructured its portfolio by voluntarily withdrawing its Malaysia marketing approval and terminating its MLSC platform licensing deal with LG Chem, concentrating resources on its core Japan and U.S. pipeline.

Per the company's disclosed schedule, first-half 2026 was to include U.S. Phase 3 IND approval, protocol disclosure, first patient dosing, and receipt and announcement of Japan's Phase 3 clinical study report—and the Japan trial indeed concluded with both primary and secondary endpoints met.

In August 2026, the first patient in the U.S. Cartistem trial was enrolled and dosed, moving the global clinical program into full execution. The company plans to file for Japanese marketing approval in the second half of 2026, targeting local approval and commercialization within 2027.

In the U.S., the single-study design cut the expected trial duration to roughly 42-45 months, and the company said it plans to pursue approval and commercialization by 2031.

Domestically, interim real-world evidence results from about 560 patients tracked more than three years post-treatment are expected to be released within the year, data the company intends to leverage for overseas regulatory filings as well.

In addition, an IND filing for a Phase 3 trial of the injectable knee osteoarthritis candidate SMUP-IA-01 is included in the second-half 2026 plan, warranting attention to pipeline progress beyond Cartistem.